Related Experiment Video

Updated: Oct 8, 2025

Eye Tracking During Visually Situated Language Comprehension: Flexibility and Limitations in Uncovering Visual Context Effects
07:36

Eye Tracking During Visually Situated Language Comprehension: Flexibility and Limitations in Uncovering Visual Context Effects

Published on: November 30, 2018

15.9K

Has the Enemy "MET" Its Match? Subgroup Analysis Results from VISION Study

Samuel Rosner1, Alexander I Spira2,3,4

  • 1Medical Oncology, Johns Hopkins Medicine Sidney Kimmel Comprehensive Cancer Center, Baltimore, Maryland.

Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|January 5, 2022
PubMed

Insights

New therapies targeting MET exon 14 skipping non-small cell lung cancer (NSCLC) are approved. Further research on tepotinib will identify patient subgroups benefiting most from this emerging treatment.

Area of Science:

  • Oncology
  • Molecular Biology
  • Genetics

Background:

  • MET exon 14 skipping mutations define a distinct molecular subtype of non-small cell lung cancer (NSCLC).
  • Recent regulatory approvals introduce novel targeted therapies for this specific NSCLC subset.
  • Tepotinib represents one such emerging therapeutic agent for MET-driven NSCLC.

Discussion:

  • Characterizing the efficacy of tepotinib across diverse patient populations is crucial.
  • Identifying predictive biomarkers may refine patient selection for optimal treatment outcomes.
  • Understanding the clinical benefit of tepotinib in various patient subgroups is essential.

Key Insights:

  • Emerging therapies, including tepotinib, offer new treatment avenues for MET exon 14 skipping NSCLC.
  • Further investigation is required to delineate patient subgroups most likely to respond to tepotinib.
  • Personalized treatment strategies are key to maximizing the benefit of novel NSCLC therapies.

Outlook:

  • Continued research will elucidate the role of tepotinib in precision oncology for NSCLC.
  • Future studies should focus on comparative effectiveness and real-world data for tepotinib.
  • Optimizing patient selection will enhance the therapeutic impact of MET-targeted agents in NSCLC.

More Related Videos

Author Spotlight: Insights into Visual Cortex Research Through Wide-View fMRI Mapping07:11

Author Spotlight: Insights into Visual Cortex Research Through Wide-View fMRI Mapping

Published on: December 8, 2023

2.0K
Development of a Gaze-Contingent Display Framework Designed for Perceptual and Oculomotor Research with Simulated Central Vision Loss07:12

Development of a Gaze-Contingent Display Framework Designed for Perceptual and Oculomotor Research with Simulated Central Vision Loss

Published on: April 11, 2025

588

Related Concept Videos

Robbers Cave04:49

Robbers Cave

During the 1950s, the landmark Robbers Cave experiment demonstrated that when groups must compete with one another, intergroup conflict, hostility, and even violence may result. At the Oklahoman summer camp, two troops of boys—termed the Rattlers and the Eagles—took part in a week-long tournament. During this time, their negativity culminated in derogatory name-calling, fistfights, and even vandalism and destruction of property. However, this work also revealed that such tension...
14.4K
Color Vision01:24

Color Vision

Color perception begins in the retina, the light-sensitive layer at the back of the eye. Two main theories explain how colors are seen: the trichromatic theory and the opponent-process theory. The trichromatic theory, proposed by Thomas Young in 1802 and extended by Hermann von Helmholtz in 1852, suggests that color vision is based on three types of cone receptors in the retina. These cones are sensitive to different but overlapping ranges of wavelengths corresponding to red, blue, and green.
860